• |
  • |
  • |
  • |
Donate

Project

PHARM - MapLight Study

Center:
Fiscal Year:
2025
Contact Information:
Project Description:
Autism Spectrum Disorder (ASD) involves challenges in social interactions, communication, and unusual sensory responses. These symptoms can include trouble with eye contact, forming relationships, and varying sensitivity to sounds or lights, leading to significant impairments in quality of life. Current therapies include behavioral and pharmacological approaches, though no approved medications exist for core symptoms. Furthermore, FDA-approved antipsychotics for irritability have significant side effects, highlighting the need for targeted treatments. This study aims to enroll 150 adolescents and adults with ASD to investigate a new treatment for social communication difficulties. Participants will be randomly assigned to receive either the treatment or a placebo. The study includes a 15-week treatment phase lasting up to 6 months. Participants can withdraw at any time.
Keyword(s):
Autism Spectrum Disorder; Medication Research; Social Communication
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities, Other
Target Audience:
Family Members/Caregivers, Adults with Disabilities, Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
International
Funding Source:
COVID-19 Related Data:
N/A